AstraZeneca will buy Alexion for $175 per share, totaling $39 billion dollars. The deal is expected to close in 2021’s third quarter.
“This acquisition allows us to enhance our presence in immunology,” AstraZeneca CEO Pascal Soriot said in a news release. “We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients.”
More articles on pharmacy:
AstraZeneca, Russia to launch joint trial of COVID-19 vaccines before end of year
Supreme Court upholds Arkansas law regulating PBMs
Timeline of CVS activity in 2020
